Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant® Touch Laser in Canada
MWN-AI** Summary
Bausch Health Companies Inc., through its aesthetics division, Solta Medical, has launched the Clear + Brilliant® Touch laser in Canada, which received Health Canada approval on May 20, 2025. This development is pivotal amid an increasing demand for non-invasive skin rejuvenation procedures in Canada. The Clear + Brilliant Touch represents the latest in dual-wavelength laser technology designed to provide customizable treatments, aligning with Canadian consumers' preferences for effective and approachable aesthetic solutions.
Thomas J. Appio, CEO of Bausch Health, emphasized Canada’s significance in the company's global expansion strategy in the aesthetics market. The laser system, initially launched in the U.S. in 2021, features an innovative design allowing practitioners to seamlessly switch between two distinct handpieces—each utilizing unique wavelengths to enhance treatment efficacy. The technology is suitable for various skin types and ages, promising minimal downtime and gentle yet effective results.
The laser's two handpieces, the 1440 nm and 1927 nm, are indicated for improving the appearance of wrinkles, pigmentation, skin texture, and pore size. As a result, it addresses early signs of aging while maintaining the skin's overall appearance, offering options suited to individual patient needs.
The Clear + Brilliant Touch system is supported by extensive clinical research, highlighting Solta Medical's commitment to leveraging evidence-based data to underline the effectiveness of its products. By expanding the availability of this advanced dermatological treatment, Bausch Health and Solta Medical are reinforcing their leadership in the aesthetics industry, catering to a growing consumer base interested in high-quality skin health solutions.
MWN-AI** Analysis
Bausch Health Companies Inc. (NYSE: BHC) is making significant strides in its aesthetics segment, particularly with the introduction of the Clear + Brilliant® Touch laser in Canada. This launch, following strong performance in the U.S. market, is tailored to meet the increasing demand for non-invasive skin rejuvenation treatments—a trend that has been gaining momentum within a demographic increasingly focused on aesthetic enhancements.
The Clear + Brilliant® Touch laser's dual-wavelength technology allows for customizable treatments, making it suitable for a broad spectrum of skin types and ages. Its introduction is timely, as Canadian consumers are increasingly seeking effective skin care solutions with minimal downtime. Given that the laser is backed by over 15 clinical studies, Bausch Health is positioned to reinforce its credibility in the aesthetic market.
From an investment perspective, Bausch Health’s continuous innovation in its Solta Medical arm indicates a commitment to maintain and potentially grow market share in the aesthetics industry. Analysts should watch for the reception of the Clear + Brilliant® Touch laser among Canadian medical practitioners and consumers alike. Positive clinical outcomes and endorsements can translate into increased sales volumes, enhancing Bausch's revenue trajectory.
However, investors should proceed with caution due to the inherent risks in the medical aesthetics space, including regulatory scrutiny and competitive pressures from other technologies. Monitoring consumer trends towards non-invasive procedures will be essential in evaluating Bausch’s growth potential.
In summary, the launch of the Clear + Brilliant® Touch laser presents a promising opportunity for Bausch Health within a growing market. While the potential for revenue growth is significant, investors should remain cognizant of market dynamics and company fundamentals when considering Bausch Health's stock as part of their portfolio.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Canada NewsWire
LAVAL, QC, Feb. 23, 2026 /CNW/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in medical aesthetics, today announced the launch of the Clear + Brilliant® Touch laser in Canada. The device was approved by Health Canada on May 20, 2025, marking an important milestone as demand for non?invasive skin rejuvenation treatments continues to grow across Canada. With this approval, Canadian physicians are able to offer one of the most advanced dual-wavelength laser technologies on the market, expanding access to customizable treatments that align with the country's growing preference for effective yet approachable skin rejuvenation options.
"The Solta business continues to expand its global presence through its diverse and well-established portfolio that supports the growing demand for high-quality aesthetics solutions," said Thomas J. Appio, Chief Executive Officer, Bausch Health. "Canada is an important part of that growth, reflecting strong and sustained interest in the aesthetic market across the country."
Building on the successful U.S. launch of the Clear + Brilliant Touch System in 2021, the device's innovative design allows for seamless use of two handpieces with unique wavelengths to deliver comprehensive treatments that help reveal smoother, more radiant, youthful-looking skin. The System is suitable for all skin types, a wide range of ages, can be used year-round (at the discretion of the treating physician) and is recognized for its ease of use, minimal downtime and gentle and effective results.
"Expanding the availability of the Clear + Brilliant Touch System into Canada marks a significant step forward for Solta Medical and its commitment to global expansion of our innovative portfolio of products in skin health," said Jiny Kim, Senior Vice President, Solta Medical, Bausch Health. "This launch reinforces Solta's leadership in supporting both providers and patients with technology that delivers safe, effective and customizable results."
Clear + Brilliant® Touch Laser Indications (Canada)
The Clear + Brilliant® Touch System is indicated for use in dermatological procedures requiring the coagulation of soft tissue and general skin resurfacing. The system includes two distinct fractional laser handpieces, each with its own indication:
1440 nm Handpiece
- Indicated for the treatment of and improvement in the appearance of:
- Wrinkles
- Dyschromia
- Pigmentation
- Skin texture
- Pore size
1927 nm Handpiece
- Indicated for the treatment of and improvement in the appearance of:
- Wrinkles
- Dyschromia
- Pigmentation
- Skin texture
- Enhancement of skin permeability
- Pore Size
About the Clear + Brilliant® Touch Laser
Solta Medical's Clear + Brilliant® Touch laser is now available in Canada, joining the Clear + Brilliant® portfolio. Supported by robust, evidence?based data, including more than 15 clinical studies, the Clear + Brilliant® laser platform uses fractional laser technology to create structural and functional changes in the skin. In Canada, these treatments help address early signs of aging, maintain youthful?looking skin, and improve the skin's overall appearance.
Since 2011, the Clear + Brilliant® platform has helped define the laser-treatment landscape across global markets.
For more information and Important Safety Information about the use of the Clear + Brilliant® Touch laser, visit ca.clearandbrilliant.com/hcp.
About Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. Our aesthetic business, Solta Medical, is a global leader in the aesthetics market, whose vision is to develop and support trusted aesthetic brands that provide value to our customers and patients. More information about Solta Medical can be found at www.solta.com. For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn.
Forward-looking Statements
This news release may contain forward-looking statements within the meaning of applicable securities laws, including the Safe Harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of the words "will," "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions. These statements are neither historical facts nor assurances of future performance, are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's overall business, including those more fully described in Bausch Health's most recent annual and quarterly reports and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to update any of these forward-looking statements to reflect events, information or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.
BHC-PRODUCTS | |
Investor Contact: | Media Contact: |
Garen Sarafian | Katie Savastano |
(877) 281-6642 (toll free) | (908) 569-3692 |
SOURCE Bausch Health Companies Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/February2026/23/c6422.html
FAQ**
How does the launch of the Clear + Brilliant® Touch laser in Canada align with the growth strategy of Bausch Health Companies Inc. BHC in the aesthetics market?
What specific advantages does the dual-wavelength technology of the Clear + Brilliant® Touch laser offer compared to Bausch Health Companies Inc. BHC's previous aesthetic products?
Can you elaborate on the clinical evidence supporting the effectiveness of the Clear + Brilliant® Touch laser from Bausch Health Companies Inc. BHC, particularly regarding safety and patient outcomes?
How does Bausch Health Companies Inc. BHC plan to educate healthcare providers in Canada about the benefits and usage of the Clear + Brilliant® Touch laser to ensure successful adoption and patient satisfaction?
**MWN-AI FAQ is based on asking OpenAI questions about Bausch Health Companies Inc. (TSXC: BHC:CC).
NASDAQ: BHC:CC
BHC:CC Trading
-0.34% G/L:
$5.88 Last:
1,784,767 Volume:
$5.90 Open:
